ANVISA provides regulatory approval for drugs and other products seeking to enter the large and growing Brazilian market.
In addition to ANVISA certification, Celerion’s Belfast facility has also been certified by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).
The facility has received both Standard and Supplementary Accreditation from the MHRA, which certifies that the general standards for study participant safety and access to emergency medical response have been met.
Celerion president and CEO Susan Thornton said by earning ANVISA certification to conduct early clinical studies and bioanalytical research for compounds destined for Brazil, Celerion is able to serve their clients’ growing needs.